title: Rapidly rising pretransplant hematocrit and hematocrit > or = 30% signal independent risks for delayed function and primary nonfunction in primary cadaveric renal transplantation.
authors.affiliation: Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI 48202.
authors.forename: R
authors.initials: R
authors.lastname: Schmidt
authors.forename: W
authors.initials: W
authors.lastname: Kupin
authors.forename: F
authors.initials: F
authors.lastname: Dumler
authors.forename: K K
authors.initials: KK
authors.lastname: Venkat
authors.forename: M
authors.initials: M
authors.lastname: Mozes
mesh_terms: D000961:Antilymphocyte Serum / Q000627:therapeutic use; D002102:Cadaver; D004359:Drug Therapy, Combination; D006400:Hematocrit; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D016853:Muromonab-CD3 / Q000627:therapeutic use; D012189:Retrospective Studies; D012307:Risk Factors; D014019:Tissue Donors
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3